Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
BMS Recruiting Study icon

Recruiting

Trial ID AZA-MDS-006  |   NCT01688011

Connect® Myeloid Disease Registry

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Summary

  • Male and Female Gender icon
  • 18+
    Age Range
  • 90
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Patients must be able to provide written informed consent form (ICF)
    1. Must be willing and able to complete baseline and follow-up HRQoL instruments, for which patients must be proficient in either English or Spanish
      1. AML patients must be at least 55 years of age at the time of informed consent.
        1. MF, ICUS, and MDS patients must be at least 18 years of age at the time of informed consent. Newly diagnosed Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) patients:
          1. Newly diagnosed primary or secondary disease. To be considered "newly diagnosed", a patient's confirmed diagnosis must be made no more than 60 days prior to the date of consent signature. (An additional 5-day window [i.e., up to 65 days prior to the date of ICF signature] may be allowed in special circumstance upon sponsor approval)
            1. Cohort assignment confirmed by central eligibility review. Cohort assignment must also be confirmed by the site. Myelofibrosis (MF) patients:
              1. Patients who initiated their first active systemic treatment for MF and/or MF-related cytopenias within 90 days prior to the date of consent signature. This cohort allows the enrollment of subjects with a diagnosis of Myelodysplastic/Myeloproliferative overlap syndromes (MDS/MPN overlap syndrome).
                1. Cohort assignment is confirmed by the site. Central eligibility review is not required. Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS) patients:
                  1. Patients who have initiated first active treatment regimen containing at least one non-ESA therapy, within 90 days prior to ICF
                    1. Cohort assignment is confirmed by site. Central eligibility review is not required. Luspatercept treated patients:
                      1. Patient must have been at least 18 years of age at the start of luspatercept.
                        1. Among LR-MDS patients, patient must have initiated luspatercept on or after September 1, 2023, must be ESA-naïve and luspatercept must be the first active treatment (as monotherapy or part of a treatment regimen) for their disease.
                          1. Among all other myeloid malignancies, there is no date restriction for initiation of luspatercept .Patient may have received prior treatment for their disease.
                            1. Patient must have at least 3 months of follow-up from start of luspatercept treatment at the participating site.

                              Exclusion Criteria

                              Exclusion Criteria Icon
                              :
                              • Suspected or proven acute promyelocytic leukemia (APL) (FAB M3 or WHO 2008) based on morphology, immunophenotype, molecular assay or karyotype
                                1. Currently enrolled in any interventional clinical trial where the patient is being treated with an investigational product that cannot be identified.
                                  1. Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS) patients who received or are receiving active (disease modifying) therapy for the treatment of MDS prior to the date of informed consent.
                                    1. Acute Myeloid Leukemia (AML) patients who initiated active (disease modifying treatment for AML more than 2 weeks prior to the date of consent.
                                      1. Myelofibrosis (MF) and Myelodysplastic/Myeloproliferative (MDS/MPN) overlap syndrome patients with suspected juvenile myelomonocytic leukemia (JMML). Luspatercept treated patients:
                                        1. Patient must not be currently or previously enrolled in the Connect Myeloid Registry.
                                          1. Patient must not have received luspatercept as part of a clinical trial.
                                            Additional Information *

                                            Treatment Options

                                            Study Arms

                                            ASSIGNED INTERVENTION

                                            Study Arms

                                            Luspatercept treated cohort (LTC)

                                            ASSIGNED INTERVENTION
                                            • Drug: Luspatercept

                                            Study Arms

                                            Newly diagnosed Acute Myeloid Leukemia (AML)

                                            ASSIGNED INTERVENTION

                                            Study Arms

                                            Newly diagnosed Higher-Risk Myelodysplastic Syndromes (HR-MDS)

                                            ASSIGNED INTERVENTION

                                            Study Arms

                                            Newly diagnosed Idiopathic cytopenia of undetermined significance (ICUS)

                                            ASSIGNED INTERVENTION

                                            Study Arms

                                            Newly diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)

                                            ASSIGNED INTERVENTION

                                            Study Arms

                                            Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS)

                                            ASSIGNED INTERVENTION

                                            Study Arms

                                            Treated Myelofibrosis (MF)

                                            ASSIGNED INTERVENTION
                                            Please select a study site to register
                                            Select a Study Site Location
                                            Select a study site location that is convenient for you
                                            Register
                                            Provide your contact details for the study site to connect with you.

                                            Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you